Pathological Processes
5
2
2
1
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
8 treatments under study, led by Gadoversetamide
Research Leaders
12 sponsors active, led by Amphia Hospital
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
20.0%
1 terminated out of 5 trials
50.0%
-36.6% vs benchmark
40%
2 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (5)
This Study is the Clinical Validation Study for Validation for the Digital Pathology System 'SGi 1.0 + EPW 1.0 + Compatible Clinical Displays'
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Adenosine as an Adjunct to Blood Cardioplegia
Pilot Study to Identify the Influence of Genetic Profile Aberrations on Patients With Recurrent Hernias
Research Network
Common Treatments
- Gadoversetamide1
- Lactulose 667 Milligrammilliliter Oral Solution1
- Normal Controls1
- Rifaximin 550 Milligram Oral Tablet Xifaxan1
- Mri1
Active Sponsors
- Amphia Hospital1
- Maastricht University Medical Center1
- University of Missouri-Columbia1
- University Medical Center Groningen1
- Guerbet1
Top Investigators
Amphia Hospital
University of Missouri-Columbia
Mallinckrodt
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Related Conditions
- Cardiomyopathies1
- Cirrhosis Liver1
- Hepatic Encephalopathy1
- Liver Diseases1
- Confirmed Diagnosis Of Alcoholic Liver Cirrhosis1